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Abstract 11 
Background: Network meta-analyses (NMAs) of psoriasis treatments, undertaken as part of 12 
the NICE Single Technology Appraisal (STA) process, have included heterogeneous studies. 13 
When there is inconsistency or heterogeneity across the different comparisons or trials within 14 
the network of studies, the results of the NMA may not be valid. We explored the impact of 15 
including studies with heterogeneous patient characteristics on the results of NMAs of 16 
psoriasis treatments. 17 
Methods: All NMAs undertaken for psoriasis STAs were identified and the included studies 18 
tabulated, including patient characteristics that may influence relative treatment effects. In 19 
addition to the original network of all studies using licensed treatment doses, a range of 20 
smaller, less heterogeneous networks were mapped: µQRSUHYLRXVELRORJLFXVH¶<25% 21 
patients had prior biologic therapy H[SRVXUHµPsoriasis Area and Severity Index score ¶22 
µZHLJKW NJ¶DQGµZKLWHHWKQLFLW\¶90% patients were white). 23 
0DQXVFULSWFOHDQFRS\ &OLFNKHUHWRDFFHVVGRZQORDG0DQXVFULSW65+HWHURJHQHLW\LQSVRULDVLV10$V5HYLVHG0D\FOHDQFRS\GRF[
&OLFNKHUHWRYLHZOLQNHG5HIHUHQFHV
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Results: Sixty-nine studies were included in our synthesis (34,924 participants). A random 1 
effects model with a log-normal prior distribution was chosen for each of the subgroup 2 
NMAs. Heterogeneity was reduced for the four smaller networks. 3 
There were no significant differences in the relative treatment effect (PASI 75 response) for 4 
each treatment across the five NMAs, with all credible intervals overlapping, although there 5 
were noticeable differences. Treatment rankings based on the median relative risks were also 6 
generally consistent across the networks. However, the NMA that included only studies in 7 
which <25% patients had prior biologic therapy exposure had slightly different treatment 8 
rankings; the anti-TNF therapies certolizumab pegol and infliximab ranked higher in this 9 
network than any other network, although credible intervals were large. 10 
Conclusions: This work has highlighted potential differences in treatment response for 11 
biologic-naïve patients. When conducting NMAs in any area, heterogeneity in patient 12 
characteristics of included trials should be carefully assessed and effect modification related 13 
to certain patient characteristics investigated through clinically relevant subgroup analyses. 14 
Key words 15 
Heterogeneity, Indirect comparison, Network meta-analysis, Single Technology Appraisal, 16 
Psoriasis 17 
Background 18 
Network meta-analysis (NMA) has become increasingly popular over recent years for 19 
estimating the relative effectiveness of several treatments in the absence of direct head-to-20 
head evidence. When direct and indirect evidence is combined in a meta-analysis, there is a 21 
risk that patients in different trials differ in terms of demographics, disease or other patient 22 
characteristics. There can also be differences in trial specific features, such as country of 23 
origin and trial design. If these differences are effect modifiers, they can result in between-24 
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study heterogeneity and create biased comparisons. In a NMA context, such biases and 1 
heterogeneity can also lead to inconsistency, i.e. conflict between direct and indirect evidence 2 
on the same comparison. It is therefore important to adjust for effect modifiers in a NMA; 3 
this can be done by restricting inclusion in the NMA to certain subgroups of patients with 4 
similar characteristics or by conducting meta-regression. Focusing the inclusion criteria on 5 
key participant or study characteristics to produce smaller, more homogenous networks can 6 
reduce the risk of both heterogeneity and inconsistency, and give more valid results.(1) 7 
Alternatively, meta-regression, on for example the average weight or proportion of included 8 
patients with certain characteristics, can also be conducted. When conducting network meta-9 
regression, a sufficient number of studies is needed to estimate independent coefficients for 10 
each treatment comparison. Otherwise, additional assumptions of common regression 11 
coefficients must be made, which may not be clinically plausible. In addition, results are 12 
often uncertain and hard to interpret. Therefore it is often more useful to identify clinically 13 
meaningful discrete participant and study characteristics which could be expected to lead to 14 
different decisions, and restrict inclusion in the NMA. 15 
Previous work carried out for the National Institute for Health and Care Excellence (NICE) 16 
has highlighted that several NMAs undertaken for NICE Single Technology Appraisals 17 
(STAs) of psoriasis treatments have included heterogeneous studies. However, the very short 18 
timeframe of a STA does not allow sufficient time to fully explore the impact of 19 
heterogeneity on the NMA results.(2) Therefore, this small methodological project aimed to 20 
explore the impact of heterogeneous patient characteristics on the results of a NMA, using 21 
data from NICE STAs of psoriasis treatments, since we identified this as an area where 22 
previous NMAs have included studies with heterogeneous patient characteristics. 23 
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There have been several NICE STAs of systemic therapies for the second-line treatment of 1 
moderate-to-severe plaque psoriasis. Psoriasis is a chronic, inflammatory immune-mediated 2 
skin disorder with a prevalence of around 3% in the UK.(3) Standard first-line treatment 3 
includes topical therapy, or systemic non-biologic therapies or phototherapy for patients with 4 
more severe disease. For adults with moderate-to-severe psoriasis who do not respond to, are 5 
intolerant of, or have a contraindication to standard systemic therapies and phototherapy, 6 
NICE recommends systemic biologic therapies, apremilast or dimethyl fumarate.  7 
The severity of psoriasis is measured using the Psoriasis Area and Severity Index (PASI), 8 
which combines the assessment of severity of lesions and the area affected into a single score. 9 
PASI is also used to assess response to psoriasis treatment, presented as a percentage 10 
response rate; PASI 75 response is a 75% or greater improvement in PASI score, PASI 90 11 
response is a 90% or greater improvement and PASI 100 response is 100% improvement in 12 
PASI score (total skin clearance). 13 
The key objectives of this methodological project were: 14 
(i) To identify NMAs undertaken as part of a STA of a second-line therapy for 15 
moderate to severe plaque psoriasis; 16 
(ii) To identify and tabulate all relevant studies included in the NMAs, recording 17 
patient and study characteristics that may influence relative treatment effects 18 
(PASI response); 19 
(iii)To map a range of smaller, less heterogeneous networks; and 20 
(iv) To run the NMAs and compare results with the results of the overall network 21 
of evidence. 22 
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Methods 1 
Two researchers (RW and SS) independently screened the NICE website for STAs of second-2 
line therapies for moderate to severe plaque psoriasis that included a NMA. The researchers 3 
also identified any sensitivity analyses undertaken by the company who undertook the NMA, 4 
as an indication of the characteristics that may be considered to have an impact on relative 5 
treatment effectiveness. 6 
All studies included in the NMAs were tabulated. Additional RCTs of second-line therapies 7 
for psoriasis were not sought since the search strategies used in the STAs were adequate and 8 
the aim of this methodological project was to compare results of NMA subgroups with the 9 
original network, rather than to update the previous NMAs. Details of important patient and 10 
study characteristics that may influence relative treatment effects were tabulated, such as 11 
timeframe at which treatment response was assessed, drug dose, concomitant psoriatic 12 
arthritis and prior treatments received (i.e. biologic naïve versus biologic experienced 13 
patients). Dermatologists who had acted as clinical advisors to the Centre for Reviews and 14 
Dissemination/Centre for Health Economics Technology Assessment Group in previous 15 
STAs of second-line therapies for psoriasis were emailed regarding their opinion on the 16 
characteristics considered most likely to have an impact on the relative effectiveness of 17 
psoriasis treatments on PASI response. The outcome used in the analysis was PASI 75 18 
response, as it is the most widely reported response outcome in the included trials and is used 19 
as a measure of treatment response in clinical practice. 20 
Study details were obtained from tables presented as part of the STA of brodalumab,(4) 21 
supplemented with data presented in primary study reports, where necessary. The 22 
brodalumab appraisal was chosen as the primary source of data because it included 23 
comprehensive study characteristics tables. The tables were independently checked for 24 
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accuracy and completeness by a second researcher using tables from two different STAs, 1 
supplemented with data presented in primary study reports. All missing data/discrepancies 2 
were added/corrected using the original study reports. 3 
Study and patient characteristics considered most likely to have an impact on relative 4 
treatment effectiveness were compared for each of the primary studies. New networks, 5 
including only studies with similar study and patient characteristics, were defined and 6 
mapped using the netmeta package(5) in R.(6) This package uses contrast-level data to create 7 
plots of all the trials included in the NMA, highlighting the number of trials between each 8 
treatment. All networks were checked for connectivity, making sure that all interventions 9 
were directly connected to at least one other intervention, forming one linked network. 10 
Binomial logit-link models were used for the NMAs.(2) Both fixed effect and random effects 11 
models were fitted for each network. The choice of prior distributions for the between-study 12 
variance was also explored. Model fit was assessed by comparing the total residual deviance 13 
to the number of data points in the model. Models were compared using the deviance 14 
information criterion (DIC) which accounts for model fit and complexity. The model with a 15 
lower DIC (a difference in value of 3 is seen as meaningful) was selected. Where the DIC 16 
were within 3 points of each other, the simplest model with fewer parameters was chosen.  17 
Results 18 
Review of NICE Technology Appraisals 19 
There have been ten NICE STAs of systemic therapies for the second-line treatment of 20 
moderate-to-severe plaque psoriasis. The second-line systemic therapies that have been 21 
appraised are the anti-tumour necrosis factor (TNF) alpha therapies adalimumab, infliximab 22 
and certolizumab pegol, the anti-interleukin (IL)-12/23 ustekinumab, the anti-IL-17 therapies 23 
secukinumab, ixekizumab and brodalumab, the anti-IL-23 tildrakizumab, the anti-24 
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phosphodiesterase (PDE) 4 apremilast and the nuclear factor (erythroid-derived 2)-like 2 1 
(Nrf2) activator dimethyl fumarate. Other than infliximab, which is only recommended for 2 
patients with very severe disease, each of the company submissions included a NMA (see 3 
Table 1).   4 
Table 1: NICE Single Technology Appraisals of systemic therapies for psoriasis that 5 
include network meta-analyses 6 
Psoriasis systemic 
therapy 
Treatment class Number of trials 
included in NMA 
Sensitivity analyses undertaken 
Adalimumab 
(TA146, 2008)(7) 
Anti-TNF-alpha 18 randomised 
controlled trials 
(RCTs) 
N/A 
Ustekinumab 
(TA180, 2009)(8) 
Anti-IL-12/23 20 RCTs N/A 
Secukinumab 
(TA350, 2015)(9) 
Anti-IL-17 26 RCTs Baseline PASI score; psoriasis duration; 
prior biologic therapy exposure; baseline 
Dermatology Life Quality Index (DLQI) 
score 
Apremilast (TA419, 
2016)(10) 
Anti-PDE4 22 RCTs Prior biologic therapy exposure 
Ixekizumab 
(TA442, 2017)(11) 
Anti-IL-17 40 RCTs All treatment doses (base case included only 
NICE-approved doses) 
Dimethyl fumarate 
(TA475, 2017)(12) 
Nrf2 activator 37 RCTs N/A 
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Brodalumab 
(TA511, 2018)(4) 
Anti-IL-17 59 RCTs NICE-approved treatment doses; timing of 
primary outcome assessment; trial size; prior 
biologic therapy exposure; baseline PASI 
score 
Certolizumab pegol 
(TA574, 2019)(13) 
Anti-TNF-alpha 65 RCTs Prior biologic therapy exposure 
Tildrakizumab 
(TA575, 2019)(14) 
Anti-IL-23 45 RCTs Timing of primary outcome assessment 
 1 
Patient characteristics that may contribute to heterogeneity in relative treatment effects 2 
Sensitivity analyses undertaken alongside the STA NMAs related to the following 3 
study/patient characteristics: size of the trial; licensed and NICE approved treatment doses; 4 
WLPLQJRISULPDU\RXWFRPHDVVHVVPHQWSDWLHQWV¶EDVHOLQH3$6,VFRUHSDWLHQWV¶EDVHOLQH5 
DLQI score; duration of disease; and prior exposure to biologic therapy. Two dermatologists 6 
(Professor Catherine Smith and Dr Phil Hampton) provided advice on the study and patient 7 
characteristics considered most likely to have an impact on the relative effectiveness of 8 
psoriasis treatments on PASI response. Important characteristics for which adequate data 9 
were available in the studies of psoriasis treatments were patient weight, exposure to previous 10 
biologic therapy, white versus non-white ethnicity and baseline PASI score. 11 
Network identification  12 
We identified 72 studies from previous NMAs of STAs of second-line therapies for moderate 13 
to severe plaque psoriasis. We excluded any studies with unlicensed treatments or treatment 14 
doses, of which there were two. One study was excluded due to the results being unpublished. 15 
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Therefore, we included 69 studies in our synthesis (34,924 participants). Characteristics of 1 
patients included in the 69 RCTs included in the networks are presented in Additional file 1. 2 
The impact of four patient characteristics on relative treatment effectiveness was investigated 3 
by producing four smaller networks: µno previous biologic use¶ (<25% patients had prior 4 
exposure to a biologic therapy), µ3$6,¶ (average PASI score was 25 or less), µweight 5 
 kg¶ (average weight was 90 kg or less) and µwhite ethnicity¶ SDWLHQWVZHUHZKLWH. 6 
Cut-off choice was informed by clinical opinion as well as being pragmatically chosen in 7 
order to ensure a sufficient number of studies was still included in each network. The studies 8 
included in each of the four networks and the original (all licensed doses) network are listed 9 
in Table 2. The network diagrams are shown in Figures 1 to 5. The width of the connecting 10 
lines is proportional to the number of trial level comparisons available and the size of the 11 
nodes is proportional to the number of patients who received the corresponding treatment. 12 
Insert Table 2 here 13 
Model fit  14 
In all models both a uniform (0,3) prior distribution and an empirically based log normal (-15 
2.70,1.522) informative prior distribution(15) were used. The random effects model with a 16 
uniform prior distribution was found to have a superior fit for the network of all studies with 17 
licensed doses (Table 3) as the residual deviance was closer to the number of unconstrained 18 
data points than the fixed effects model and the random effects model with log-normal prior 19 
distribution. The deviance information criterion (DIC) was also lower for the uniform prior 20 
random effects model than the other two models. 21 
Insert Table 3 here 22 
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The random effects model with a log-normal prior distribution was chosen for the network of 1 
patients with no previous biologic use (<25% patients had previous biologic use), the 2 
QHWZRUNRISDWLHQWVZLWK3$6,VFRUH25WKHQHWZRUNRISDWLHQWVZLWKZHLJKW90 kg and the 3 
network of 90% white patients (Table 3). The DIC and residual deviance was much lower 4 
for the random effects models than the fixed effects models. Although the DIC was very 5 
similar between the random effects models, the log-normal prior model was chosen as it had 6 
a much smaller number of parameters (pD) than the uniform prior model.  7 
Heterogeneity 8 
The network of all studies with licensed doses had the highest between-study heterogeneity 9 
(0.31, 95% CrI: 0.17-0.45). The between-study heterogeneity was reduced for the four 10 
smaller networks, which all had similar values. However, the network of patients with no 11 
previous biologic use had the smallest heterogeneity (0.14, 95% CrI: 0.09-0.23), alongside 12 
WKHQHWZRUNRISDWLHQWVZLWKZHLJKW kg (0.15, 95% CrI: 0.09-0.24). The densities of the 13 
posterior between-study heterogeneity for each network meta-analysis are shown in Figure 6. 14 
Effects of the interventions 15 
Relative risk ratios for each treatment compared against placebo are shown in Table 4. 16 
Across the five NMAs, the relative risks for each treatment appear to be similar, with all 17 
credible intervals overlapping. However, there are some noticeable differences. Etanercept 50 18 
mg (once-weekly) had a higher relative treatment effect of achieving PASI 75 in the licensed 19 
doses network (10.67, 95% CrI: 7.96-13.53) compared to all other networks and methotrexate 20 
had a higher relative effect in the network of patients with no previous biologic use (<25% 21 
had previous use) (10.47, 95% CrI: 6.73-14.41) compared to the other networks. In the 22 
white patients network, secukinumab had a higher relative treatment effect than in all other 23 
networks (18.67, 95% CrI: 16.22-20.81) and guselkumab had a lower relative treatment effect 24 
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compared to all the other networks (15.30, 95% CrI: 10.89-18.39). However, their credible 1 
intervals were large. 2 
Insert table 4 here 3 
Log-odds ratios for each network and for each treatment compared to placebo are shown in 4 
Figure 7. Absolute probabilities of achieving PASI 75 for each treatment across the five 5 
networks are shown in Additional file 2.  6 
The median rankings of treatments based on the relative risks are shown in Table 5. 7 
Ixekizumab ranks best in all networks, except the network with predominantly white patients, 8 
in which secukinumab ranks best. Dimethyl fumarate ranks worst in all five networks. The 9 
rankings are generally consistent across the networks. However, the NMA that included only 10 
studies in which less than 25% of patients had prior exposure to a biologic therapy had 11 
slightly different treatment rankings; the anti-TNF therapies certolizumab pegol (median rank 12 
of 8 [95% CrI: 2-13] for the 200mg dose and 6 [95% CrI: 1-11] for the 400 mg dose) and 13 
infliximab (median rank of 3 [95% CrI: 3-11]) ranked higher in this network group than any 14 
of the other networks, indicating that these two therapies may work better in patients who 15 
have not previously received biologic therapy, although we note the large uncertainty in these 16 
rankings. However, biologic experienced patients are more likely to have had prior exposure 17 
to an anti-TNF therapy (i.e. adalimumab or etanercept) which may explain why subsequent 18 
response to the anti-TNF therapies certolizumab pegol and infliximab was lower in the 19 
networks that did not include primarily biologic-naïve patients. 20 
Insert table 5 here 21 
The network of primarily white patients also had slightly different treatment rankings; 22 
secukinumab ranked higher and guselkumab ranked lower than in the other networks, 23 
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although there was large uncertainty for the guselkumab result. Data on ethnicity was often 1 
not reported in the included studies, so some assumptions had to be made based on the 2 
location of the study when extracting data from primary studies, adding further uncertainty to 3 
the results for this network. 4 
Sensitivity analysis 5 
Some studies of the earlier treatments for psoriasis, adalimumab, etanercept and infliximab, 6 
did not report prior biologic use, however they may have had largely biologic-naïve patient 7 
populations as biologics were not widely available at the time they were conducted. 8 
Therefore, all the studies not already included in the network of patients who had no prior 9 
biologic exposure (<25% patients) were screened and studies conducted prior to 2007, where 10 
prior biologic use was not reported, were added to the network. The cut-off of 2007 was 11 
chosen to ensure that all the earliest studies were included. Six studies conducted prior to 12 
2007 were identified and included in the network: Gottlieb et al. (2003),(16) Leonardi et al. 13 
(2003),(17) Papp et al. (2005),(18) Reich et al. (2005),(19) Gordon et al (2006)(20) and 14 
Tyring et al. (2006).(21) The random effects model with a log-normal prior distribution was 15 
chosen for the network of patients with no previous biologic use (<25% patients had previous 16 
biologic use) (see Additional file 3, Table 1).  17 
The results from the sensitivity analysis were very similar to the main results (see Additional 18 
file 3, Table 2). There were minimal changes to the risk ratios, with very little difference in 19 
the anti-TNF drugs adalimumab, infliximab and etanercept. There were a few small changes 20 
to other treatments. The median ranking of guselkumab changed from 3 to 4, with the same 21 
credible interval of 1-7. The median ranking of apremilast and DMF dropped one rank each, 22 
with the addition of etanercept 25 mg to the network, making the total number of treatments 23 
17, rather than 16.  24 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
Discussion 1 
The smaller networks investigated were less heterogeneous, with between-study standard 2 
deviation ranging from 0.14 (95% CrI: 0.09-0.23) for the network of patients with no 3 
previous biologic use to 0.17 (95% CrI: 0.10-0.25) for the network of predominantly white 4 
patients, in comparison with the network of all studies with licensed doses (0.31, 95% CrI: 5 
0.17-0.45). The reduction in heterogeneity in the network of patients with no previous 6 
biologic use could be due to the population being more clinically homogenous. Previous 7 
biologic use may be an important effect modifier and so excluding patients with previous 8 
biologic use may have removed a significant source of heterogeneity. 9 
Results for most of the NMAs were consistent, in terms of treatment rankings for PASI 75 10 
response. The main exception was the NMA of studies in which 25% patients had prior 11 
exposure to a biologic therapy; in this network results were better for the anti-TNF therapies 12 
certolizumab pegol and infliximab than in the other networks. Whilst this could simply reflect 13 
the fact that studies in which a higher proportion of patients had prior exposure to a biologic 14 
therapy had used an anti-TNF as the prior therapy (i.e. adalimumab or etanercept), this may 15 
be an important effect modifier. Prior biologic therapy exposure was the most commonly 16 
conducted sensitivity analysis amongst the NICE STAs of systemic therapies for psoriasis 17 
that included a NMA (see Table 1) and our results confirm the importance of considering this 18 
as a potential effect modifier. 19 
Meta-regression is another method commonly used to adjust for effect modifiers. However, 20 
this requires a sufficient number of studies in order to estimate independent coefficients for 21 
each treatment comparison. Additional file 4 presents the number of studies that reported 22 
each continuous covariate for each treatment comparison. This shows that there are not 23 
enough studies between comparisons to estimate independent coefficients and a common 24 
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regression coefficient would need to be assumed, which may not be clinically credible. 1 
Therefore, analyses were simplified by dichotomising variables according to clinically 2 
relevant cut-offs and creating separate networks. Previous work has investigated the effect of 3 
baseline risk using meta-regression.(22) Baseline risk is often a proxy for multiple observed 4 
and unobserved effect modifiers and does not describe specific individual patient-related 5 
treatment effect modifiers. Adjusting for baseline risk in this analysis may not be clinically 6 
meaningful for decision making since it is uncertain what determines the baseline risk. Our 7 
aim was to characterise heterogeneity based on known and previously hypothesised study-8 
level characteristics that translate to individual patient characteristics, which can be used to 9 
focus decision-making on more specific, homogeneous populations. 10 
A limitation of our analysis is the variation in time point at which PASI 75 was assessed in 11 
the included studies. In most included studies the time point for the primary efficacy 12 
assessment was week 12, although in some studies it was week 16; adalimumab, apremilast, 13 
certolizumab pegol, tildrakizumab and ustekinumab were assessed at week 12 in some 14 
studies and week 16 in others. The primary efficacy assessment was week 10 in placebo-15 
controlled trials of infliximab, reflecting the shorter time to treatment effect for this therapy. 16 
Our findings could be investigated further using individual patient data meta-analysis 17 
accounting for different important covariates. However, this preliminary approach has 18 
highlighted potential differences in treatment response for patients with prior exposure to 19 
biologic therapy. Where individual patient data are available, a better characterisation of 20 
SDWLHQWV¶SULRUELRORJLFXVHFRXOGEHXVHGWRIXUWKHUH[SORUHWKHGLIIHUHQFHVLGHQWLILHG 21 
Comparison with other results 22 
7UHDWPHQWUDQNLQJVIRUWKHµOLFHQFHGGRVHV¶NMA were broadly consistent with the results of 23 
the NMA undertaken by the guideline development group for the BAD guidelines for 24 
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biologic therapy for psoriasis, published in April 2017.(23) The BAD NMA compared 1 
ixekizumab, secukinumab, infliximab, ustekinumab, adalimumab, etanercept, methotrexate 2 
and placebo. Interventions were ranked in order of efficacy using the surface under the 3 
cumulative ranking (SUCRA) curve method. For the outcome PASI 75 at 3-4 months 4 
ixekizumab ranked best (SUCRA 96.4, mean rank 1.3), followed by infliximab (SUCRA 5 
81.2, mean rank 2.3), secukinumab (SUCRA 79.0, mean rank 2.5), ustekinumab (SUCRA 6 
51.9, mean rank 4.4), adalimumab (SUCRA 48.7, mean rank 4.6), etanercept (SUCRA 28.4, 7 
mean rank 6.0), methotrexate (SUCRA 14.5, mean rank 7.0) and placebo (SUCRA 0, mean 8 
rank 8.0). However, the BAD NMA pooled licensed and unlicensed doses.(24) It included 9 
many unlicensed doses that were not included in this analysis as they are not relevant for 10 
decision-making. Naïve pooling across doses, without accounting for possible differential 11 
dose effects, is not recommended as it can increase heterogeneity due to different treatment 12 
definitions. Furthermore, the aim of this analysis was to characterise heterogeneity in 13 
networks used by NICE, therefore only licenced doses were relevant. 14 
A recent article evaluated the association between patient characteristics and response to 15 
biologic therapies for psoriasis, using a multicentre longitudinal cohort study; the British 16 
Association of Dermatologists Biologic Interventions Register (BADBIR).(25) This study 17 
also found little evidence for predictors of differential treatment response, although only 18 
biologic-naïve patients were included in the study. 19 
Network structure 20 
There was some overlap between networks in terms of included studies (see Table 2). In 21 
particular many of the studies excluded from tKHZKLWHSDWLHQWVQHWZRUNZHUH included 22 
LQWKHQHWZRUNRIVWXGLHVZLWKOLJKWHUSDWLHQWVNJ2QO\WHQVWXGLHVLQFOXGHGSDWLHQWV23 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
with a mean weight below 80 kg, nine of which were conducted in Japanese, Chinese or 1 
mixed Taiwanese, Chinese and Korean patients (See Additional file 1). 2 
Recommendations for future research 3 
NMAs of psoriasis treatments undertaken in the future should investigate heterogeneity 4 
within the networks and include clinically relevant subgroups to further investigate effect 5 
modification related to certain patient characteristics. This recommendation is also 6 
appropriate for NMAs in other clinical areas and other fields outside of medicine. 7 
Conclusions 8 
This work has highlighted potential differences in relative treatment effectiveness for 9 
biologic-naïve patients receiving psoriasis treatment. Our results support the assumption that 10 
prior exposure to biologic therapy is associated with psoriasis treatment response and confirm 11 
the importance of considering this as a potential effect modifier. Future decision-making on 12 
psoriasis treatments should consider SDWLHQWV¶SULRUH[SRVXUHWRELRORJLFWKHUDSLHV. 13 
More broadly, we have demonstrated the importance of assessing heterogeneity in patient 14 
characteristics and adjusting for effect modifiers in a NMA, which can be done by restricting 15 
inclusion in the NMA to certain subgroups of patients with similar characteristics. Focusing 16 
the inclusion criteria to produce smaller, more homogenous networks can reduce the risk of 17 
both heterogeneity and inconsistency, and give more valid results. 18 
List of abbreviations 19 
BADBIR British Association of Dermatologists Biologic Interventions Register 20 
DLQI  Dermatology Life Quality Index 21 
DIC  Deviance information criterion 22 
IL  Interleukin 23 
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NMA  Network meta-analysis 1 
Nrf2  Nuclear factor (erythroid-derived 2)-like 2 2 
PDE  Phosphodiesterase 3 
PASI   Psoriasis Area and Severity Index 4 
RCT  Randomised controlled trial 5 
STA  Single Technology Appraisal 6 
SUCRA Surface under the cumulative ranking 7 
TNF  Tumour necrosis factor 8 
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Table 2: Studies included in each network meta-analysis 1 
Studies All 
licensed 
doses 
(N=69) 
Patients 
with no 
previous 
biologic use 
(<25% had 
previous 
use) 
(N=34) 
Patients 
with PASI 
VFRUH25 
(N=59) 
Patients 
with weight 
 kg 
(N=28) 
White 
patients 
(90% 
white) 
(N=42) 
AMAGINE1 2016 9  9  9 
AMAGINE2 2015 9  9  9 
AMAGINE3 2015 9 9 9 9 9 
Nakagawa 2016 9 9  9  
Papp 2012 9  9 9  
CHAMPION 2008 9  9 9 9 
Goldminz 2015 9  9   
Cai 2016 9 9  9  
REVEAL 2008 9 9 9  9 
Asahina 2010 9   9  
Gordon 2006 9  9  9 
XPLORE 2015 9  9  9 
Bissonnette 2013 9  9  9 
VOYAGE1 2017 9 9 9   
VOYAGE2 2017 9 9 9   
PSOR005 2012 9  9  9 
ESTEEM1 2015 9  9  9 
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ESTEEM2 2015 9  9  9 
Ohtsuki 2017 9 9 9 9  
LIBERATE 2016 9 9 9 9 9 
Leonardi 2003 9  9   
Gottlieb 2003 9  9  9 
Papp 2005 9  9  9 
VandeKerkhof 2008 9  9 9 9 
Bagel 2012 9 9 9   
Bachelez 2015 9 9 9 9  
Tyring 2006 9  9   
PRISTINE 2013 9 9 9 9  
M10114 2011 9 9 9  9 
M10315 2011 9 9 9  9 
reSURFACE2 9 9 9 9 9 
PIECE 2016 9 9 9  9 
Yang 2012 9  9 9  
EXPRESS 2005 9  9 9  
Chaudhari 2001 9 9 9 9 9 
SPIRIT 2004 9  9  9 
EXPRESSII 2007 9 9 9  9 
Torii 2010 9   9  
RESTORE1 2011 9 9 9 9 9 
UNCOVER1 2016 9  9  9 
UNCOVER2 2015 9 9 9  9 
UNCOVER3 2015 9 9 9  9 
IXORAS 2017 9 9 9 9 9 
FEATURE 2015 9  9  9 
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ERASURE 2014 9  9 9  
FIXTURE 2014 9 9 9 9  
JUNCTURE 2015 9 9 9  9 
CLEAR 2015 9 9 9 9  
PEARL 2011 9 9 9 9  
PHOENIX1 2008 9  9  9 
PHOENIX2 2008 9  9  9 
LOTUS 2013 9 9 9 9  
ACCEPT 2010 9 9 9  9 
Igarashi 2012 9 9  9  
BRIDGE 2017 9 9 9  9 
Caproni 2009 9  9  9 
Gisondi 2008 9  9  9 
Meffert 9    9 
PappD 2015 9 9    
ReSURFACE1 9 9 9 9  
ultIMMA1 9     
ultIMMA2 9     
METOP 9 9 9  9 
Krueger 9  9   
Reich 2012 9 9 9 9 9 
CIMPACT 2018 9  9 9 9 
CIMPASI1 2018 9  9  9 
CIMPASI2 2018 9  9  9 
UNVEIL 9 9 9 9 9 
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Table 3: Measures of goodness of fit of fixed and random effects models for each of the 1 
five network meta-analyses.  2 
Measure of goodness of fit Random effects 
(uniform prior) 
Random effects 
(log-normal 
prior) 
Fixed effects 
Licensed doses network 
Residual deviance1 162.78 177.54 209.77 
pD 117.98 106.29 91.61 
Deviance information criterion 
(DIC) 
280.76 283.83 301.38 
Between-study standard deviation, 
posterior median (95% credible 
interval) 
0.31 (0.17-0.45) 0.19 (0.12-0.28) - 
Network of patients with no previous biologic use (<25% had previous use) 
Residual deviance2 82.10 82.88 88.85 
pD 59.12 56.3 52.45 
Deviance information criterion 
(DIC) 
141.22 139.20 141.30 
Between-study standard 
deviation, posterior median (95% 
credible interval) 
0.19 (0.01-0.41) 0.14 (0.09-0.23) - 
Network of patients with PASI score 25 
Residual deviance3 143.89 152.67 173.06 
pD 99.16 90.58 79.61 
Deviance information criterion 
(DIC) 
243.05 243.26 252.67 
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Between-study standard deviation, 
posterior median (95% credible 
interval) 
0.2574 (0.114-
0.408) 
0.16 (0.10-0.24) - 
Network of patients with weight 90 kg 
Residual deviance4 66.40 74.17 80.02 
pD 51.59 44.78 42.14 
Deviance information criterion 
(DIC) 
117.99 118.95 122.16 
Between-study standard deviation, 
posterior median (95% credible 
interval) 
0.40 (0.08-0.76) 0.15 (0.09-0.24) - 
Network of 90% white patients  
Residual deviance5 100.57 112.47 126.65 
pD 78.57 71.62 63.83 
Deviance information criterion 
(DIC) 
179.14 184.09 190.48 
Between-study standard deviation, 
posterior median (95% credible 
interval) 
0.311 (0.13-0.51) 0.17 (0.10-0.25) - 
1165 unconstrained data points, pD number of parameters for Licensed doses network 280 unconstrained data points, pD 1 
number of parameters 3143 unconstrained data points, pD number of parameters 465 unconstrained data points, 2 
pD number of parameters 5103 unconstrained data points, pD number of parameters 3 
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Table 4: Median risk ratio for each treatment compared against placebo in all five network 1 
meta-analyses 2 
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Treatment 
Median risk ratio versus placebo ± PASI 75 
 (95% CrI) 
All licensed 
doses 
No previous 
biologic use (<25%)  
PASI score 
 
:HLJKW 
kg 
ZKLWH
patients 
Adalimumab 40 mg 
12.74 
(11.00-14.49) 
12.48 
(10.91-14.13) 
13.09 
(11.72-14.57) 
12.87 
(10.29-15.39) 
13.18 
(11.21-15.15) 
Brodalumab 210 mg 
16.76 
(15.12-18.53) 
16.45 
(14.66-18.31) 
16.62 
(15.20-18.18) 
16.73 
(14.97-18.58) 
16.56 
(15.02-18.24) 
Certolizumab 200 mg 
12.07 
(9.62-14.54) 
13.93 
(8.63-18.20) 
12.08 
(10.30-13.94) 
11.71 
(9.11-14.27) 
12.13 
(10.02-14.26) 
Certolizumab 400 mg 
13.47 
(11.09-15.80) 
15.73 
(10.81-19.08) 
13.42 
(11.65-15.23) 
13.04 
(10.53-15.46) 
13.48 
(11.42-15.52) 
Etanercept 25 mg 
7.61 
(5.52-10.11) 
- 7.64 
(6.20-9.20) 
- 7.89 
(5.60-10.51) 
Etanercept 50 mg 
once-weekly 
10.67 
(7.96-13.53) 
5.08 
(3.50-7.07) 
6.16 
(4.69-7.90) 
5.57 
(3.91-7.65) 
7.07 
(4.57-10.20) 
Etanercept 50 mg 
twice per week 
9.90 
(8.68-11.21) 
9.46 
(8.27-10.77) 
10.40 
(9.47-11.40) 
9.85 
(8.27-11.55) 
10.33 
(9.01-11.75) 
Guselkumab 100 mg 
17.06 
(15.30-18.91) 
16.68 
(15.07-18.42) 
16.83 
(15.32-18.46) 
- 15.30 
(10.89-18.39) 
Infliximab 5 mg 
16.22 
(14.37-18.15) 
16.88 
(14.66-19.03) 
15.46 
(13.85-17.17) 
14.19 
(11.76-16.56) 
15.38 
(13.41-17.36) 
Ixekizumab 80mg  
17.64 
(16.06-19.36) 
17.42 
(15.89-19.09) 
17.79 
(16.30-19.41) 
17.16 
(14.67-19.33) 
17.75 
(16.23-19.41) 
Risankizumab 150 mg 
16.46 
(14.37-18.47) 
- - - - 
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Secukinumab 300 mg 
16.45 
(14.79-18.23) 
16.03 
(14.41-17.73) 
16.43 
(15.03-17.96) 
16.12 
(14.55-17.82) 
18.67 
(16.22-20.81) 
Ustekinumab 45 mg 
13.59 
(11.79-15.44) 
12.20 
(10.32-14.14) 
13.46 
(12.17-14.84) 
13.04 
(10.35-15.63) 
13.68 
(11.95-15.48) 
Ustekinumab 90 mg 
14.67 
(12.85-16.54) 
13.36 
(11.29-15.38) 
14.51 
(13.20-15.95) 
14.36 
(10.18-17.57) 
14.64 
(13.00-16.37) 
Ustekinumab (45 mg 
or 90 mg) 
12.85 
(11.07-14.67) 
12.96 
(11.05-14.94) 
13.19 
(11.79-14.66) 
13.11 
(10.99-15.20) 
13.14 
(11.35-14.95) 
Tildrakizumab 100 mg 
14.86 
(12.49-17.02) 
15.03 
(13.18-16.91) 
15.82 
(14.25-17.50) 
15.28 
(13.31-17.21) 
16.21 
(14.20-18.16) 
Apremilast  
5.80 
(4.20-7.61) 
3.77 
(2.48-5.59) 
5.17 
(4.01-6.61) 
3.91 
(2.60-5.79) 
5.46 
(4.12-7.10) 
Dimethyl Fumarate 
2.97 
(1.44-5.73) 
2.97 
(1.77-4.88) 
2.97 
(1.71-5.01) 
- 2.96 
(1.71-4.98) 
Fumaderm 
3.31 
(1.62-6.26) 
3.32 
(1.97-5.41) 
3.31 
(1.94-5.53) 
- 3.30 
(1.92-5.48) 
Methotrexate 
6.15 
(4.07-8.65) 
10.47 
(6.73-14.41) 
6.50 
(4.69-8.60) 
5.49 
(3.56-8.12) 
6.30 
(4.37-8.61) 
Acitretin 
4.024 
(1.55-8.39) 
- 4.07 
(1.59-8.29) 
- 4.29 
(1.74-8.43) 
Cyclosporin 1.5 mg 
8.10 
(2.41-16.91) 
- - - 2.14 
(0.38-10.53) 
Cyclosporin 2.5 mg 
7.10 
(2.02-16.34) 
- - - 6.76 
(2.07-16.03) 
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Table 5: Median rank of treatments according to PASI 75 response in each of the five 1 
networks 2 
 
 
Treatment 
                         Median rank (95% CrI)  
Licensed 
Doses 
N=69 
No previous 
biologic use 
(<25%)  
N=34 
PASI score 
 
N=59 
Weight  
90 kg 
N=27 
90% white 
patients 
N=42 
Adalimumab 
 
11 (8-14) 11 (8-12) 10 (7-12) 9 (5-11) 10 (7-12) 
Apremilast 
 
 
17 (16-18) 15 (14-16) 16 (15-16) 14 (13-14) 16 (15-16) 
Brodalumab 
 
3 (1-6) 4 (1-7) 3 (2-5) 2 (1-4) 4 (2-6) 
Certolizumab 200 mg 
 
13 (9-15) 8 (2-13) 12 (9-12) 11 (7-12) 12 (8-13) 
Certolizumab 400 mg 
 
10 (7-13) 6 (1-11) 9 (7-11) 8 (5-11) 9 (6-11) 
DMF 
 
18 (17-18) 16 (14-16) 17 (17-17) - 17 (17-17) 
Etanercept 25mg 
 
16 (15-17) - 14 (14-15) - 14 (13-16) 
Etanercept 50mg 
(twice per week) 
 
15 (14-15) 13 (12-13) 13 (13-13) 12 (11-12) 13 (12-14) 
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 1 
Etanercept 50mg  
(once-weekly) 
 
14 (10-16) 14 (14-15) 15 (14-16) 13 (13-14) 15 (13-16) 
Guselkumab 
 
2 (1-6) 3 (1-7) 2 (2-5) - 6 (2-12) 
Infliximab 
 
5 (2-8) 3 (1-7) 6 (3-7) 6 (3-10) 5 (3-9) 
Ixekizumab 
 
1 (1-4) 1 (1-4) 1 (1-1) 1 (1-5) 2 (1-3) 
Risankizumab 
 
4 (1-8) - - - - 
Secukinumab 
 
4 (2-7) 5 (2-7) 4 (2-6) 3 (1-5) 1 (1-3) 
Tildrakizumab 
 
7 (4-12) 7 (4-9) 5 (3-7) 4 (2-7) 4 (3-7) 
Ustekinumab 45 mg 
 
10 (8-13) 11 (8-12) 9 (8-12) 8 (5-11) 9 (6-12) 
Ustekinumab 45  
mg/90 mg 
 
11 (8-14) 10 (7-12) 10 (7-12) 8 (5-11) 10 (6-12) 
Ustekinumab 90 mg 
 
8 (5-10) 9 (7-12) 7 (6-8) 6 (1-11) 7 (5-9) 
Total number of 
treatments 
18 16 17 14 17 
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Research article 1 
Patient characteristics as effect modifiers for psoriasis biologic treatment response: an 2 
assessment using network meta-analysis subgroups  3 
Mrs Ros Wade, Research Fellow, Centre for Reviews and Dissemination, University of York, 4 
York YO10 5DD. Email: ros.wade@york.ac.uk. Telephone: 01904 321051 (corresponding 5 
author) 6 
Ms Sahar Sharif-Hurst, Research Fellow, Centre for Reviews and Dissemination, University 7 
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Professor Sofia Dias, Professor in Health Technology Assessment, Centre for Reviews and 9 
Dissemination, University of York, York YO10 5DD. Email: sofia.dias@york.ac.uk 10 
Abstract 11 
Background: Network meta-analyses (NMAs) of psoriasis treatments, undertaken as part of 12 
the NICE Single Technology Appraisal (STA) process, have included heterogeneous studies. 13 
When there is inconsistency or heterogeneity across the different comparisons or trials within 14 
the network of studies, the results of the NMA may not be valid. We explored the impact of 15 
including studies with heterogeneous patient characteristics on the results of NMAs of 16 
psoriasis treatments. 17 
Methods: All NMAs undertaken for psoriasis STAs were identified and the included studies 18 
tabulated, including patient characteristics that may influence relative treatment effects. In 19 
addition to the original network of all studies using licensed treatment doses, a range of 20 
smaller, less heterogeneous networks were mapped: µQRSUHYLRXVELRORJLFXVH¶<25% 21 
patients had prior biologic therapy H[SRVXUHµPsoriasis Area and Severity Index score ¶22 
µZHLJKW NJ¶DQGµZKLWHHWKQLFLW\¶90% patients were white). 23 
0DQXVFULSWWUDFNFKDQJHV &OLFNKHUHWRDFFHVVGRZQORDG0DQXVFULSW65+HWHURJHQHLW\LQSVRULDVLV10$V5HYLVHG0D\WUDFNHGGRF[
&OLFNKHUHWRYLHZOLQNHG5HIHUHQFHV
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Results: Sixty-nine studies were included in our synthesis (34,924 participants). A random 1 
effects model with a log-normal prior distribution was chosen for each of the subgroup 2 
NMAs. Heterogeneity was reduced for the four smaller networks. 3 
There were no significant differences in the relative treatment effect (PASI 75 response) for 4 
each treatment across the five NMAs, with all credible intervals overlapping, although there 5 
were noticeable differences. Treatment rankings based on the median relative risks were also 6 
generally consistent across the networks. However, the NMA that included only studies in 7 
which <25% patients had prior biologic therapy exposure had slightly different treatment 8 
rankings; the anti-TNF therapies certolizumab pegol and infliximab ranked higher in this 9 
network than any other network, although credible intervals were large. 10 
Conclusions: This work has highlighted potential differences in treatment response for 11 
biologic-naïve patients. When conducting NMAs in any area, heterogeneity in patient 12 
characteristics of included trials should be carefully assessed and effect modification related 13 
to certain patient characteristics investigated through clinically relevant subgroup analyses. 14 
Key words 15 
Heterogeneity, Indirect comparison, Network meta-analysis, Single Technology Appraisal, 16 
Psoriasis 17 
Background 18 
Network meta-analysis (NMA) has become increasingly popular over recent years for 19 
estimating the relative effectiveness of several treatments in the absence of direct head-to-20 
head evidence. When direct and indirect evidence is combined in a meta-analysis, there is a 21 
risk that patients in different trials differ in terms of demographics, disease or other patient 22 
characteristics. There can also be differences in trial specific features, such as country of 23 
origin and trial design. If these differences are effect modifiers, they can result in between-24 
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study heterogeneity and create biased comparisons. In a NMA context, such biases and 1 
heterogeneity can also lead to inconsistency, i.e. conflict between direct and indirect evidence 2 
on the same comparison. It is therefore important to adjust for effect modifiers in a NMA; 3 
this can be done by restricting inclusion in the NMA to certain subgroups of patients with 4 
similar characteristics or by conducting meta-regression. Focusing the inclusion criteria on 5 
key participant or study characteristics to produce smaller, more homogenous networks can 6 
reduce the risk of both heterogeneity and inconsistency, and give more valid results.(1) 7 
Alternatively, meta-regression, on for example the average weight or proportion of included 8 
patients with certain characteristics, can also be conducted. When conducting network meta-9 
regression, a sufficient number of studies is needed to estimate independent coefficients for 10 
each treatment comparison. Otherwise, additional assumptions of common regression 11 
coefficients must be made, which may not be clinically plausible. In addition, results are 12 
often uncertain and hard to interpret. Therefore it is often more useful to identify clinically 13 
meaningful discrete participant and study characteristics which could be expected to lead to 14 
different decisions, and restrict inclusion in the NMA. 15 
Previous work carried out for the National Institute for Health and Care Excellence (NICE) 16 
has highlighted that several NMAs undertaken for NICE Single Technology Appraisals 17 
(STAs) of psoriasis treatments have included heterogeneous studies. However, the very short 18 
timeframe of a STA does not allow sufficient time to fully explore the impact of 19 
heterogeneity on the NMA results.(2) Therefore, this small methodological project aimed to 20 
explore the impact of heterogeneous patient characteristics on the results of a NMA, using 21 
data from NICE STAs of psoriasis treatments, since we identified this as an area where 22 
previous NMAs have included studies with heterogeneous patient characteristics. 23 
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There have been several NICE STAs of systemic therapies for the second-line treatment of 1 
moderate-to-severe plaque psoriasis. Psoriasis is a chronic, inflammatory immune-mediated 2 
skin disorder with a prevalence of around 3% in the UK.(3) Standard first-line treatment 3 
includes topical therapy, or systemic non-biologic therapies or phototherapy for patients with 4 
more severe disease. For adults with moderate-to-severe psoriasis who do not respond to, are 5 
intolerant of, or have a contraindication to standard systemic therapies and phototherapy, 6 
NICE recommends systemic biologic therapies, apremilast or dimethyl fumarate.  7 
The severity of psoriasis is measured using the Psoriasis Area and Severity Index (PASI), 8 
which combines the assessment of severity of lesions and the area affected into a single score. 9 
PASI is also used to assess response to psoriasis treatment, presented as a percentage 10 
response rate; PASI 75 response is a 75% or greater improvement in PASI score, PASI 90 11 
response is a 90% or greater improvement and PASI 100 response is 100% improvement in 12 
PASI score (total skin clearance). 13 
The key objectives of this methodological project were: 14 
(i) To identify NMAs undertaken as part of a STA of a second-line therapy for 15 
moderate to severe plaque psoriasis; 16 
(ii) To identify and tabulate all relevant studies included in the NMAs, recording 17 
patient and study characteristics that may influence relative treatment effects 18 
(PASI response); 19 
(iii)To map a range of smaller, less heterogeneous networks; and 20 
(iv) To run the NMAs and compare results with the results of the overall network 21 
of evidence. 22 
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Methods 1 
Two researchers (RW and SS) independently screened the NICE website for STAs of second-2 
line therapies for moderate to severe plaque psoriasis that included a NMA. The researchers 3 
also identified any sensitivity analyses undertaken by the company who undertook the NMA, 4 
as an indication of the characteristics that may be considered to have an impact on relative 5 
treatment effectiveness. 6 
All studies included in the NMAs were tabulated. Additional RCTs of second-line therapies 7 
for psoriasis were not sought since the search strategies used in the STAs were adequate and 8 
the aim of this methodological project was to compare results of NMA subgroups with the 9 
original network, rather than to update the previous NMAs. Details of important patient and 10 
study characteristics that may influence relative treatment effects were tabulated, such as 11 
timeframe at which treatment response was assessed, drug dose, concomitant psoriatic 12 
arthritis and prior treatments received (i.e. biologic naïve versus biologic experienced 13 
patients). Dermatologists who had acted as clinical advisors to the Centre for Reviews and 14 
Dissemination/Centre for Health Economics Technology Assessment Group in previous 15 
STAs of second-line therapies for psoriasis were emailed regarding their opinion on the 16 
characteristics considered most likely to have an impact on the relative effectiveness of 17 
psoriasis treatments on PASI response. The outcome used in the analysis was PASI 75 18 
response, as it is the most widely reported response outcome in the included trials and is used 19 
as a measure of treatment response in clinical practice. 20 
Study details were obtained from tables presented as part of the STA of brodalumab,(4) 21 
supplemented with data presented in primary study reports, where necessary. The 22 
brodalumab appraisal was chosen as the primary source of data because it included 23 
comprehensive study characteristics tables. The tables were independently checked for 24 
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accuracy and completeness by a second researcher using tables from two different STAs, 1 
supplemented with data presented in primary study reports. All missing data/discrepancies 2 
were added/corrected using the original study reports. 3 
Study and patient characteristics considered most likely to have an impact on relative 4 
treatment effectiveness were compared for each of the primary studies. New networks, 5 
including only studies with similar study and patient characteristics, were defined and 6 
mapped using the netmeta package(5) in R.(6) This package uses contrast-level data to create 7 
plots of all the trials included in the NMA, highlighting the number of trials between each 8 
treatment. All networks were checked for connectivity, making sure that all interventions 9 
were directly connected to at least one other intervention, forming one linked network. 10 
Binomial logit-link models were used for the NMAs.(2) Both fixed effect and random effects 11 
models were fitted for each network. The choice of prior distributions for the between-study 12 
variance was also explored. Model fit was assessed by comparing the total residual deviance 13 
to the number of data points in the model. Models were compared using the deviance 14 
information criterion (DIC) which accounts for model fit and complexity. The model with a 15 
lower DIC (a difference in value of 3 is seen as meaningful) was selected. Where the DIC 16 
were within 3 points of each other, the simplest model with fewer parameters was chosen.  17 
Results 18 
Review of NICE Technology Appraisals 19 
There have been ten NICE STAs of systemic therapies for the second-line treatment of 20 
moderate-to-severe plaque psoriasis. The second-line systemic therapies that have been 21 
appraised are the anti-tumour necrosis factor (TNF) alpha therapies adalimumab, infliximab 22 
and certolizumab pegol, the anti-interleukin (IL)-12/23 ustekinumab, the anti-IL-17 therapies 23 
secukinumab, ixekizumab and brodalumab, the anti-IL-23 tildrakizumab, the anti-24 
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phosphodiesterase (PDE) 4 apremilast and the nuclear factor (erythroid-derived 2)-like 2 1 
(Nrf2) activator dimethyl fumarate. Other than infliximab, which is only recommended for 2 
patients with very severe disease, each of the company submissions included a NMA (see 3 
Table 1).   4 
Table 1: NICE Single Technology Appraisals of systemic therapies for psoriasis that 5 
include network meta-analyses 6 
Psoriasis systemic 
therapy 
Treatment class Number of trials 
included in NMA 
Sensitivity analyses undertaken 
Adalimumab 
(TA146, 2008)(7) 
Anti-TNF-alpha 18 randomised 
controlled trials 
(RCTs) 
N/A 
Ustekinumab 
(TA180, 2009)(8) 
Anti-IL-12/23 20 RCTs N/A 
Secukinumab 
(TA350, 2015)(9) 
Anti-IL-17 26 RCTs Baseline PASI score; psoriasis duration; 
prior biologic therapy exposure; baseline 
Dermatology Life Quality Index (DLQI) 
score 
Apremilast (TA419, 
2016)(10) 
Anti-PDE4 22 RCTs Prior biologic therapy exposure 
Ixekizumab 
(TA442, 2017)(11) 
Anti-IL-17 40 RCTs All treatment doses (base case included only 
NICE-approved doses) 
Dimethyl fumarate 
(TA475, 2017)(12) 
Nrf2 activator 37 RCTs N/A 
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Brodalumab 
(TA511, 2018)(4) 
Anti-IL-17 59 RCTs NICE-approved treatment doses; timing of 
primary outcome assessment; trial size; prior 
biologic therapy exposure; baseline PASI 
score 
Certolizumab pegol 
(TA574, 2019)(13) 
Anti-TNF-alpha 65 RCTs Prior biologic therapy exposure 
Tildrakizumab 
(TA575, 2019)(14) 
Anti-IL-23 45 RCTs Timing of primary outcome assessment 
 1 
Patient characteristics that may contribute to heterogeneity in relative treatment effects 2 
Sensitivity analyses undertaken alongside the STA NMAs related to the following 3 
study/patient characteristics: size of the trial; licensed and NICE approved treatment doses; 4 
WLPLQJRISULPDU\RXWFRPHDVVHVVPHQWSDWLHQWV¶EDVHOLQH3$6,VFRUHSDWLHQWV¶EDVHOLQH5 
DLQI score; duration of disease; and prior exposure to biologic therapy. Two dermatologists 6 
(Professor Catherine Smith and Dr Phil Hampton) provided advice on the study and patient 7 
characteristics considered most likely to have an impact on the relative effectiveness of 8 
psoriasis treatments on PASI response. Important characteristics for which adequate data 9 
were available in the studies of psoriasis treatments were patient weight, exposure to previous 10 
biologic therapy, white versus non-white ethnicity and baseline PASI score. 11 
Network identification  12 
We identified 72 studies from previous NMAs of STAs of second-line therapies for moderate 13 
to severe plaque psoriasis. We excluded any studies with unlicensed treatments or treatment 14 
doses, of which there were two. One study was excluded due to the results being unpublished. 15 
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Therefore, we included 69 studies in our synthesis (34,924 participants). Characteristics of 1 
patients included in the 69 RCTs included in the networks are presented in Additional file 1. 2 
The impact of four patient characteristics on relative treatment effectiveness was investigated 3 
by producing four smaller networks: µno previous biologic use¶ (<25% patients had prior 4 
exposure to a biologic therapy), µ3$6,¶ (average PASI score was 25 or less), µweight 5 
 kg¶ (average weight was 90 kg or less) and µwhite ethnicity¶ SDWLHQWVZHUHZKLWH. 6 
Cut-off choice was informed by clinical opinion as well as being pragmatically chosen in 7 
order to ensure a sufficient number of studies was still included in each network. The studies 8 
included in each of the four networks and the original (all licensed doses) network are listed 9 
in Table 2. The network diagrams are shown in Figures 1 to 5. The width of the connecting 10 
lines is proportional to the number of trial level comparisons available and the size of the 11 
nodes is proportional to the number of patients who received the corresponding treatment. 12 
Insert Table 2 here 13 
Model fit  14 
In all models both a uniform (0,3) prior distribution and an empirically based log normal (-15 
2.70,1.522) informative prior distribution(15) were used. The random effects model with a 16 
uniform prior distribution was found to have a superior fit for the network of all studies with 17 
licensed doses (Table 3) as the residual deviance was closer to the number of unconstrained 18 
data points than the fixed effects model and the random effects model with log-normal prior 19 
distribution. The deviance information criterion (DIC) was also lower for the uniform prior 20 
random effects model than the other two models. 21 
Insert Table 3 here 22 
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The random effects model with a log-normal prior distribution was chosen for the network of 1 
patients with no previous biologic use (<25% patients had previous biologic use), the 2 
QHWZRUNRISDWLHQWVZLWK3$6,VFRUH25WKHQHWZRUNRISDWLHQWVZLWKZHLJKW90 kg and the 3 
network of 90% white patients (Table 3). The DIC and residual deviance was much lower 4 
for the random effects models than the fixed effects models. Although the DIC was very 5 
similar between the random effects models, the log-normal prior model was chosen as it had 6 
a much smaller number of parameters (pD) than the uniform prior model.  7 
Heterogeneity 8 
The network of all studies with licensed doses had the highest between-study heterogeneity 9 
(0.31, 95% CrI: 0.17-0.45). The between-study heterogeneity was reduced for the four 10 
smaller networks, which all had similar values. However, the network of patients with no 11 
previous biologic use had the smallest heterogeneity (0.14, 95% CrI: 0.09-0.23), alongside 12 
WKHQHWZRUNRISDWLHQWVZLWKZHLJKW kg (0.15, 95% CrI: 0.09-0.24). The densities of the 13 
posterior between-study heterogeneity for each network meta-analysis are shown in Figure 6. 14 
Effects of the interventions 15 
Relative risk ratios for each treatment compared against placebo are shown in Table 4. 16 
Across the five NMAs, the relative risks for each treatment appear to be similar, with all 17 
credible intervals overlapping. However, there are some noticeable differences. Etanercept 50 18 
mg (once-weekly) had a higher relative treatment effect of achieving PASI 75 in the licensed 19 
doses network (10.67, 95% CrI: 7.96-13.53) compared to all other networks and methotrexate 20 
had a higher relative effect in the network of patients with no previous biologic use (<25% 21 
had previous use) (10.47, 95% CrI: 6.73-14.41) compared to the other networks. In the 22 
white patients network, secukinumab had a higher relative treatment effect than in all other 23 
networks (18.67, 95% CrI: 16.22-20.81) and guselkumab had a lower relative treatment effect 24 
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compared to all the other networks (15.30, 95% CrI: 10.89-18.39). However, their credible 1 
intervals were large. 2 
Insert table 4 here 3 
Log-odds ratios for each network and for each treatment compared to placebo are shown in 4 
Figure 7. Absolute probabilities of achieving PASI 75 for each treatment across the five 5 
networks are shown in Additional file 2.  6 
The median rankings of treatments based on the relative risks are shown in Table 5. 7 
Ixekizumab ranks best in all networks, except the network with predominantly white patients, 8 
in which secukinumab ranks best. Dimethyl fumarate ranks worst in all five networks. The 9 
rankings are generally consistent across the networks. However, the NMA that included only 10 
studies in which less than 25% of patients had prior exposure to a biologic therapy had 11 
slightly different treatment rankings; the anti-TNF therapies certolizumab pegol (median rank 12 
of 8 [95% CrI: 2-13] for the 200mg dose and 6 [95% CrI: 1-11] for the 400 mg dose) and 13 
infliximab (median rank of 3 [95% CrI: 3-11]) ranked higher in this network group than any 14 
of the other networks, indicating that these two therapies may work better in patients who 15 
have not previously received biologic therapy, although we note the large uncertainty in these 16 
rankings. However, biologic experienced patients are more likely to have had prior exposure 17 
to an anti-TNF therapy (i.e. adalimumab or etanercept) which may explain why subsequent 18 
response to the anti-TNF therapies certolizumab pegol and infliximab was lower in the 19 
networks that did not include primarily biologic-naïve patients. 20 
Insert table 5 here 21 
The network of primarily white patients also had slightly different treatment rankings; 22 
secukinumab ranked higher and guselkumab ranked lower than in the other networks, 23 
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although there was large uncertainty for the guselkumab result. Data on ethnicity was often 1 
not reported in the included studies, so some assumptions had to be made based on the 2 
location of the study when extracting data from primary studies, adding further uncertainty to 3 
the results for this network. 4 
Sensitivity analysis 5 
Some studies of the earlier treatments for psoriasis, adalimumab, etanercept and infliximab, 6 
did not report prior biologic use, however they may have had largely biologic-naïve patient 7 
populations as biologics were not widely available at the time they were conducted. 8 
Therefore, all the studies not already included in the network of patients who had no prior 9 
biologic exposure (<25% patients) were screened and studies conducted prior to 2007, where 10 
prior biologic use was not reported, were added to the network. The cut-off of 2007 was 11 
chosen to ensure that all the earliest studies were included. Six studies conducted prior to 12 
2007 were identified and included in the network: Gottlieb et al. (2003),(16) Leonardi et al. 13 
(2003),(17) Papp et al. (2005),(18) Reich et al. (2005),(19) Gordon et al (2006)(20) and 14 
Tyring et al. (2006).(21) The random effects model with a log-normal prior distribution was 15 
chosen for the network of patients with no previous biologic use (<25% patients had previous 16 
biologic use) (see Additional file 3, Table 1).  17 
The results from the sensitivity analysis were very similar to the main results (see Additional 18 
file 3, Table 2). There were minimal changes to the risk ratios, with very little difference in 19 
the anti-TNF drugs adalimumab, infliximab and etanercept. There were a few small changes 20 
to other treatments. The median ranking of guselkumab changed from 3 to 4, with the same 21 
credible interval of 1-7. The median ranking of apremilast and DMF dropped one rank each, 22 
with the addition of etanercept 25 mg to the network, making the total number of treatments 23 
17, rather than 16.  24 
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Discussion 1 
The smaller networks investigated were less heterogeneous, with between-study standard 2 
deviation ranging from 0.14 (95% CrI: 0.09-0.23) for the network of patients with no 3 
previous biologic use to 0.17 (95% CrI: 0.10-0.25) for the network of predominantly white 4 
patients, in comparison with the network of all studies with licensed doses (0.31, 95% CrI: 5 
0.17-0.45). The reduction in heterogeneity in the network of patients with no previous 6 
biologic use could be due to the population being more clinically homogenous. Previous 7 
biologic use may be an important effect modifier and so excluding patients with previous 8 
biologic use may have removed a significant source of heterogeneity. 9 
Results for most of the NMAs were consistent, in terms of treatment rankings for PASI 75 10 
response. The main exception was the NMA of studies in which 25% patients had prior 11 
exposure to a biologic therapy; in this network results were better for the anti-TNF therapies 12 
certolizumab pegol and infliximab than in the other networks. Whilst this could simply reflect 13 
the fact that studies in which a higher proportion of patients had prior exposure to a biologic 14 
therapy had used an anti-TNF as the prior therapy (i.e. adalimumab or etanercept), this may 15 
be an important effect modifier. Prior biologic therapy exposure was the most commonly 16 
conducted sensitivity analysis amongst the NICE STAs of systemic therapies for psoriasis 17 
that included a NMA (see Table 1) and our results confirm the importance of considering this 18 
as a potential effect modifier. 19 
Meta-regression is another method commonly used to adjust for effect modifiers. However, 20 
this requires a sufficient number of studies in order to estimate independent coefficients for 21 
each treatment comparison. Additional file 4 presents the number of studies that reported 22 
each continuous covariate for each treatment comparison. This shows that there are not 23 
enough studies between comparisons to estimate independent coefficients and a common 24 
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regression coefficient would need to be assumed, which may not be clinically credible. 1 
Therefore, analyses were simplified by dichotomising variables according to clinically 2 
relevant cut-offs and creating separate networks. Previous work has investigated the effect of 3 
baseline risk using meta-regression.(22) Baseline risk is often a proxy for multiple observed 4 
and unobserved effect modifiers and does not describe specific individual patient-related 5 
treatment effect modifiers. Adjusting for baseline risk in this analysis may not be clinically 6 
meaningful for decision making since it is uncertain what determines the baseline risk. Our 7 
aim was to characterise heterogeneity based on known and previously hypothesised study-8 
level characteristics that translate to individual patient characteristics, which can be used to 9 
focus decision-making on more specific, homogeneous populations. 10 
A limitation of our analysis is the variation in time point at which PASI 75 was assessed in 11 
the included studies. In most included studies the time point for the primary efficacy 12 
assessment was week 12, although in some studies it was week 16; adalimumab, apremilast, 13 
certolizumab pegol, tildrakizumab and ustekinumab were assessed at week 12 in some 14 
studies and week 16 in others. The primary efficacy assessment was week 10 in placebo-15 
controlled trials of infliximab, reflecting the shorter time to treatment effect for this therapy. 16 
Our findings could be investigated further using individual patient data meta-analysis 17 
accounting for different important covariates. However, this preliminary approach has 18 
highlighted potential differences in treatment response for patients with prior exposure to 19 
biologic therapy. Where individual patient data are available, a better characterisation of 20 
SDWLHQWV¶SULRUELRORJLFXVHFRXOGEHXVHGWRfurther explore the differences identified. 21 
Comparison with other results 22 
7UHDWPHQWUDQNLQJVIRUWKHµOLFHQFHGGRVHV¶NMA were broadly consistent with the results of 23 
the NMA undertaken by the guideline development group for the BAD guidelines for 24 
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biologic therapy for psoriasis, published in April 2017.(23) The BAD NMA compared 1 
ixekizumab, secukinumab, infliximab, ustekinumab, adalimumab, etanercept, methotrexate 2 
and placebo. Interventions were ranked in order of efficacy using the surface under the 3 
cumulative ranking (SUCRA) curve method. For the outcome PASI 75 at 3-4 months 4 
ixekizumab ranked best (SUCRA 96.4, mean rank 1.3), followed by infliximab (SUCRA 5 
81.2, mean rank 2.3), secukinumab (SUCRA 79.0, mean rank 2.5), ustekinumab (SUCRA 6 
51.9, mean rank 4.4), adalimumab (SUCRA 48.7, mean rank 4.6), etanercept (SUCRA 28.4, 7 
mean rank 6.0), methotrexate (SUCRA 14.5, mean rank 7.0) and placebo (SUCRA 0, mean 8 
rank 8.0). However, the BAD NMA pooled licensed and unlicensed doses.(24) It included 9 
many unlicensed doses that were not included in this analysis as they are not relevant for 10 
decision-making. Naïve pooling across doses, without accounting for possible differential 11 
dose effects, is not recommended as it can increase heterogeneity due to different treatment 12 
definitions. Furthermore, the aim of this analysis was to characterise heterogeneity in 13 
networks used by NICE, therefore only licenced doses were relevant. 14 
A recent article evaluated the association between patient characteristics and response to 15 
biologic therapies for psoriasis, using a multicentre longitudinal cohort study; the British 16 
Association of Dermatologists Biologic Interventions Register (BADBIR).(25) This study 17 
also found little evidence for predictors of differential treatment response, although only 18 
biologic-naïve patients were included in the study. 19 
Network structure 20 
There was some overlap between networks in terms of included studies (see Table 2). In 21 
particular many of the studies excluded from tKHZKLWHSDWLHQWVQHWZRUNZHUH included 22 
in the network of studies with lLJKWHUSDWLHQWVNJ2QO\WHQVWXGLHVLQFOXGHGSDWLHQWV23 
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with a mean weight below 80 kg, nine of which were conducted in Japanese, Chinese or 1 
mixed Taiwanese, Chinese and Korean patients (See Additional file 1). 2 
Recommendations for future research 3 
NMAs of psoriasis treatments undertaken in the future should investigate heterogeneity 4 
within the networks and include clinically relevant subgroups to further investigate effect 5 
modification related to certain patient characteristics. This recommendation is also 6 
appropriate for NMAs in other clinical areas and other fields outside of medicine. 7 
Conclusions 8 
This work has highlighted potential differences in relative treatment effectiveness for 9 
biologic-naïve patients receiving psoriasis treatment. Our results support the assumption that 10 
prior exposure to biologic therapy is associated with psoriasis treatment response and confirm 11 
the importance of considering this as a potential effect modifier. Future decision-making on 12 
psoriasis treatments should consider SDWLHQWV¶prior exposure to biologic therapies. this 13 
subgroup when undertaking network meta-analysis. 14 
More broadly, we have demonstrated the importance of assessing heterogeneity in patient 15 
characteristics and adjusting for effect modifiers in a NMA, which can be done by restricting 16 
inclusion in the NMA to certain subgroups of patients with similar characteristics. Focusing 17 
the inclusion criteria to produce smaller, more homogenous networks can reduce the risk of 18 
both heterogeneity and inconsistency, and give more valid results. 19 
List of abbreviations 20 
BADBIR British Association of Dermatologists Biologic Interventions Register 21 
DLQI  Dermatology Life Quality Index 22 
DIC  Deviance information criterion 23 
IL  Interleukin 24 
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NICE  National Institute for Health and Care Excellence 1 
NMA  Network meta-analysis 2 
Nrf2  Nuclear factor (erythroid-derived 2)-like 2 3 
PDE  Phosphodiesterase 4 
PASI   Psoriasis Area and Severity Index 5 
RCT  Randomised controlled trial 6 
STA  Single Technology Appraisal 7 
SUCRA Surface under the cumulative ranking 8 
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Table 2: Studies included in each network meta-analysis 1 
Studies All 
licensed 
doses 
(N=69) 
Patients 
with no 
previous 
biologic use 
(<25% had 
previous 
use) 
(N=34) 
Patients 
with PASI 
VFRUH25 
(N=59) 
Patients 
with weight 
 kg 
(N=28) 
White 
patients 
(90% 
white) 
(N=42) 
AMAGINE1 2016 9  9  9 
AMAGINE2 2015 9  9  9 
AMAGINE3 2015 9 9 9 9 9 
Nakagawa 2016 9 9  9  
Papp 2012 9  9 9  
CHAMPION 2008 9  9 9 9 
Goldminz 2015 9  9   
Cai 2016 9 9  9  
REVEAL 2008 9 9 9  9 
Asahina 2010 9   9  
Gordon 2006 9  9  9 
XPLORE 2015 9  9  9 
Bissonnette 2013 9  9  9 
VOYAGE1 2017 9 9 9   
VOYAGE2 2017 9 9 9   
PSOR005 2012 9  9  9 
ESTEEM1 2015 9  9  9 
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ESTEEM2 2015 9  9  9 
Ohtsuki 2017 9 9 9 9  
LIBERATE 2016 9 9 9 9 9 
Leonardi 2003 9  9   
Gottlieb 2003 9  9  9 
Papp 2005 9  9  9 
VandeKerkhof 2008 9  9 9 9 
Bagel 2012 9 9 9   
Bachelez 2015 9 9 9 9  
Tyring 2006 9  9   
PRISTINE 2013 9 9 9 9  
M10114 2011 9 9 9  9 
M10315 2011 9 9 9  9 
reSURFACE2 9 9 9 9 9 
PIECE 2016 9 9 9  9 
Yang 2012 9  9 9  
EXPRESS 2005 9  9 9  
Chaudhari 2001 9 9 9 9 9 
SPIRIT 2004 9  9  9 
EXPRESSII 2007 9 9 9  9 
Torii 2010 9   9  
RESTORE1 2011 9 9 9 9 9 
UNCOVER1 2016 9  9  9 
UNCOVER2 2015 9 9 9  9 
UNCOVER3 2015 9 9 9  9 
IXORAS 2017 9 9 9 9 9 
FEATURE 2015 9  9  9 
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ERASURE 2014 9  9 9  
FIXTURE 2014 9 9 9 9  
JUNCTURE 2015 9 9 9  9 
CLEAR 2015 9 9 9 9  
PEARL 2011 9 9 9 9  
PHOENIX1 2008 9  9  9 
PHOENIX2 2008 9  9  9 
LOTUS 2013 9 9 9 9  
ACCEPT 2010 9 9 9  9 
Igarashi 2012 9 9  9  
BRIDGE 2017 9 9 9  9 
Caproni 2009 9  9  9 
Gisondi 2008 9  9  9 
Meffert 9    9 
PappD 2015 9 9    
ReSURFACE1 9 9 9 9  
ultIMMA1 9     
ultIMMA2 9     
METOP 9 9 9  9 
Krueger 9  9   
Reich 2012 9 9 9 9 9 
CIMPACT 2018 9  9 9 9 
CIMPASI1 2018 9  9  9 
CIMPASI2 2018 9  9  9 
UNVEIL 9 9 9 9 9 
 1 
  2 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
25 
 
Table 3: Measures of goodness of fit of fixed and random effects models for each of the 1 
five network meta-analyses.  2 
Measure of goodness of fit Random effects 
(uniform prior) 
Random effects 
(log-normal 
prior) 
Fixed effects 
Licensed doses network 
Residual deviance1 162.78 177.54 209.77 
pD 117.98 106.29 91.61 
Deviance information criterion 
(DIC) 
280.76 283.83 301.38 
Between-study standard deviation, 
posterior median (95% credible 
interval) 
0.31 (0.17-0.45) 0.19 (0.12-0.28) - 
Network of patients with no previous biologic use (<25% had previous use) 
Residual deviance2 82.10 82.88 88.85 
pD 59.12 56.3 52.45 
Deviance information criterion 
(DIC) 
141.22 139.20 141.30 
Between-study standard 
deviation, posterior median (95% 
credible interval) 
0.19 (0.01-0.41) 0.14 (0.09-0.23) - 
Network of patients with PASI score 25 
Residual deviance3 143.89 152.67 173.06 
pD 99.16 90.58 79.61 
Deviance information criterion 
(DIC) 
243.05 243.26 252.67 
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Between-study standard deviation, 
posterior median (95% credible 
interval) 
0.2574 (0.114-
0.408) 
0.16 (0.10-0.24) - 
Network of patients with weight 90 kg 
Residual deviance4 66.40 74.17 80.02 
pD 51.59 44.78 42.14 
Deviance information criterion 
(DIC) 
117.99 118.95 122.16 
Between-study standard deviation, 
posterior median (95% credible 
interval) 
0.40 (0.08-0.76) 0.15 (0.09-0.24) - 
Network of 90% white patients  
Residual deviance5 100.57 112.47 126.65 
pD 78.57 71.62 63.83 
Deviance information criterion 
(DIC) 
179.14 184.09 190.48 
Between-study standard deviation, 
posterior median (95% credible 
interval) 
0.311 (0.13-0.51) 0.17 (0.10-0.25) - 
1165 unconstrained data points, pD number of parameters for Licensed doses network 280 unconstrained data points, pD 1 
number of parameters 3143 unconstrained data points, pD number of parameters 465 unconstrained data points, 2 
pD number of parameters 5103 unconstrained data points, pD number of parameters 3 
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Table 4: Median risk ratio for each treatment compared against placebo in all five network 1 
meta-analyses 2 
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Treatment 
Median risk ratio versus placebo ± PASI 75 
 (95% CrI) 
All licensed 
doses 
No previous 
biologic use (<25%)  
PASI score 
 
:HLJKW 
kg 
ZKLWH
patients 
Adalimumab 40 mg 
12.74 
(11.00-14.49) 
12.48 
(10.91-14.13) 
13.09 
(11.72-14.57) 
12.87 
(10.29-15.39) 
13.18 
(11.21-15.15) 
Brodalumab 210 mg 
16.76 
(15.12-18.53) 
16.45 
(14.66-18.31) 
16.62 
(15.20-18.18) 
16.73 
(14.97-18.58) 
16.56 
(15.02-18.24) 
Certolizumab 200 mg 
12.07 
(9.62-14.54) 
13.93 
(8.63-18.20) 
12.08 
(10.30-13.94) 
11.71 
(9.11-14.27) 
12.13 
(10.02-14.26) 
Certolizumab 400 mg 
13.47 
(11.09-15.80) 
15.73 
(10.81-19.08) 
13.42 
(11.65-15.23) 
13.04 
(10.53-15.46) 
13.48 
(11.42-15.52) 
Etanercept 25 mg 
7.61 
(5.52-10.11) 
- 7.64 
(6.20-9.20) 
- 7.89 
(5.60-10.51) 
Etanercept 50 mg 
once-weekly 
10.67 
(7.96-13.53) 
5.08 
(3.50-7.07) 
6.16 
(4.69-7.90) 
5.57 
(3.91-7.65) 
7.07 
(4.57-10.20) 
Etanercept 50 mg 
twice per week 
9.90 
(8.68-11.21) 
9.46 
(8.27-10.77) 
10.40 
(9.47-11.40) 
9.85 
(8.27-11.55) 
10.33 
(9.01-11.75) 
Guselkumab 100 mg 
17.06 
(15.30-18.91) 
16.68 
(15.07-18.42) 
16.83 
(15.32-18.46) 
- 15.30 
(10.89-18.39) 
Infliximab 5 mg 
16.22 
(14.37-18.15) 
16.88 
(14.66-19.03) 
15.46 
(13.85-17.17) 
14.19 
(11.76-16.56) 
15.38 
(13.41-17.36) 
Ixekizumab 80mg  
17.64 
(16.06-19.36) 
17.42 
(15.89-19.09) 
17.79 
(16.30-19.41) 
17.16 
(14.67-19.33) 
17.75 
(16.23-19.41) 
Risankizumab 150 mg 
16.46 
(14.37-18.47) 
- - - - 
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Secukinumab 300 mg 
16.45 
(14.79-18.23) 
16.03 
(14.41-17.73) 
16.43 
(15.03-17.96) 
16.12 
(14.55-17.82) 
18.67 
(16.22-20.81) 
Ustekinumab 45 mg 
13.59 
(11.79-15.44) 
12.20 
(10.32-14.14) 
13.46 
(12.17-14.84) 
13.04 
(10.35-15.63) 
13.68 
(11.95-15.48) 
Ustekinumab 90 mg 
14.67 
(12.85-16.54) 
13.36 
(11.29-15.38) 
14.51 
(13.20-15.95) 
14.36 
(10.18-17.57) 
14.64 
(13.00-16.37) 
Ustekinumab (45 mg 
or 90 mg) 
12.85 
(11.07-14.67) 
12.96 
(11.05-14.94) 
13.19 
(11.79-14.66) 
13.11 
(10.99-15.20) 
13.14 
(11.35-14.95) 
Tildrakizumab 100 mg 
14.86 
(12.49-17.02) 
15.03 
(13.18-16.91) 
15.82 
(14.25-17.50) 
15.28 
(13.31-17.21) 
16.21 
(14.20-18.16) 
Apremilast  
5.80 
(4.20-7.61) 
3.77 
(2.48-5.59) 
5.17 
(4.01-6.61) 
3.91 
(2.60-5.79) 
5.46 
(4.12-7.10) 
Dimethyl Fumarate 
2.97 
(1.44-5.73) 
2.97 
(1.77-4.88) 
2.97 
(1.71-5.01) 
- 2.96 
(1.71-4.98) 
Fumaderm 
3.31 
(1.62-6.26) 
3.32 
(1.97-5.41) 
3.31 
(1.94-5.53) 
- 3.30 
(1.92-5.48) 
Methotrexate 
6.15 
(4.07-8.65) 
10.47 
(6.73-14.41) 
6.50 
(4.69-8.60) 
5.49 
(3.56-8.12) 
6.30 
(4.37-8.61) 
Acitretin 
4.024 
(1.55-8.39) 
- 4.07 
(1.59-8.29) 
- 4.29 
(1.74-8.43) 
Cyclosporin 1.5 mg 
8.10 
(2.41-16.91) 
- - - 2.14 
(0.38-10.53) 
Cyclosporin 2.5 mg 
7.10 
(2.02-16.34) 
- - - 6.76 
(2.07-16.03) 
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Table 5: Median rank of treatments according to PASI 75 response in each of the five 1 
networks 2 
 
 
Treatment 
                         Median rank (95% CrI)  
Licensed 
Doses 
N=69 
No previous 
biologic use 
(<25%)  
N=34 
PASI score 
 
N=59 
Weight  
90 kg 
N=27 
90% white 
patients 
N=42 
Adalimumab 
 
11 (8-14) 11 (8-12) 10 (7-12) 9 (5-11) 10 (7-12) 
Apremilast 
 
 
17 (16-18) 15 (14-16) 16 (15-16) 14 (13-14) 16 (15-16) 
Brodalumab 
 
3 (1-6) 4 (1-7) 3 (2-5) 2 (1-4) 4 (2-6) 
Certolizumab 200 mg 
 
13 (9-15) 8 (2-13) 12 (9-12) 11 (7-12) 12 (8-13) 
Certolizumab 400 mg 
 
10 (7-13) 6 (1-11) 9 (7-11) 8 (5-11) 9 (6-11) 
DMF 
 
18 (17-18) 16 (14-16) 17 (17-17) - 17 (17-17) 
Etanercept 25mg 
 
16 (15-17) - 14 (14-15) - 14 (13-16) 
Etanercept 50mg 
(twice per week) 
 
15 (14-15) 13 (12-13) 13 (13-13) 12 (11-12) 13 (12-14) 
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 1 
Etanercept 50mg  
(once-weekly) 
 
14 (10-16) 14 (14-15) 15 (14-16) 13 (13-14) 15 (13-16) 
Guselkumab 
 
2 (1-6) 3 (1-7) 2 (2-5) - 6 (2-12) 
Infliximab 
 
5 (2-8) 3 (1-7) 6 (3-7) 6 (3-10) 5 (3-9) 
Ixekizumab 
 
1 (1-4) 1 (1-4) 1 (1-1) 1 (1-5) 2 (1-3) 
Risankizumab 
 
4 (1-8) - - - - 
Secukinumab 
 
4 (2-7) 5 (2-7) 4 (2-6) 3 (1-5) 1 (1-3) 
Tildrakizumab 
 
7 (4-12) 7 (4-9) 5 (3-7) 4 (2-7) 4 (3-7) 
Ustekinumab 45 mg 
 
10 (8-13) 11 (8-12) 9 (8-12) 8 (5-11) 9 (6-12) 
Ustekinumab 45  
mg/90 mg 
 
11 (8-14) 10 (7-12) 10 (7-12) 8 (5-11) 10 (6-12) 
Ustekinumab 90 mg 
 
8 (5-10) 9 (7-12) 7 (6-8) 6 (1-11) 7 (5-9) 
Total number of 
treatments 
18 16 17 14 17 
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